Mark S. Huberman

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist et al. · Clinical Cancer Research · 2006 · 584 citations

Medicine, Oncology, Pharmacology +15

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun et al. · Science Translational Medicine · 2013 · 565 citations · Full text

Medicine, Molecular Biology, Oncology +12

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan et al. · Lung Cancer · 2015 · 526 citations · Full text

Medicine, Cancer Biology, Oncology +14

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Daniel B. Costa, Balázs Halmos, Amit Kumar et al. · PLoS Medicine · 2007 · 491 citations · Full text

Medicine, Oncology, Pharmacology +17